Tülay Kuş (Tulay Kus)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 10

Top Topics

Renal Cell Carcinoma

Top Venues

Future oncology (London, England)

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

European journal of cancer care

This page only lists publications with an associated author ORCID identifier.

Publications

Tülay Kuş, Irfan Cicin
A perspective: the integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for phase II immunotherapy clinical trials. Immunotherapy 16 (5) (2024)
Hacı Arak, Bahtiyar Sahinoğlu, Tülay Kuş
The effect of examining somatic alterations with NGS in patients with solid tumors, on patient management: A single-center experience in Turkey. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)
Tülay Kuş, Irfan Cicin
A perspective: the integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for phase II immunotherapy clinical trials. Immunotherapy 16 (5) (2024)
Tülay Kuş, Irfan Cicin
A perspective: the integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for phase II immunotherapy clinical trials. Immunotherapy (2024)
Tülay Kuş, Gokmen Aktas, Irfan Cicin
Is the "P-value" Alone a Sufficient Metric for the Magnitude of Clinical Benefit and Which Clinical Trial Is Actually Positive, KEYNOTE-394 or KEYNOTE-240? The oncologist (2023)
Tülay Kuş, Gokmen Aktas
Should We Completely Exclude Locoregional Therapy for the Primary Tumor from Our Clinical Practice in De Novo Metastatic Breast Cancer? Annals of surgical oncology 29 (9) (2022)
Tülay Kuş, Elif Isbilen, Gökmen Aktaş, Hacı Arak
The predictive value of vitamin D follow-up and supplementation on recurrence in patients with colorectal cancer. Future oncology (London, England) 18 (18) (2022)
Tülay Kuş, Gökmen Aktaş, Melike Ozcelik, Merve Dirikoc, Teoman Sakalar, Abdilkerim Oyman, Ozgur Tanriverdi, Tugba Yavuzsen, Sinan Unal, Havva Yeşil Çinkir, Aykut Bahceci, Ali Alkan, Serdar Turhal, Huseyin Abali
Association of illness perception with chemotherapy-induced nausea and vomiting: a Turkish Oncology Group (TOG) study. Future oncology (London, England) 17 (15) (2021)
Ali Alkan, Hatime Arzu Yasar, Zeynep Gülsüm Sevgen Güç, Mustafa Gürbüz, Tuğba Başoğlu, Sema Sezgin Göksu, Fatma Bugdayci Basal, Hacı Mehmet Türk, Özlem Özdemir, Havva Yeşil Çinkir, Deniz Can Guven, Tülay Kuş, Sema Türker, Lokman Koral, Yusuf Karakas, Naziye Ak, Semra Paydaş, Ebru Karcı, Atike Gökçen Demiray, Atakan Demir, Özkan Alan, Özge Keskin, Erdinç Nayır, Ozgur Tanrıverdi, Tugba Yavuzsen, Perran Fulden Yumuk, Ozturk Ates, Hasan Şenol Coşkun, Nazım Serdar Turhal, Filiz Çay Şenler
Worse patient-physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG). European journal of cancer care 29 (6) (2020)
Tülay Kuş, Gokmen Aktas
Durable response after interruption of nivolumab in patients with metastatic renal cell carcinoma: Is renal toxicity a marker to predict the benefit of nivolumab? Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 26 (4) (2019)